PFA 100 Evaluation and Reference Interval HOACNY

Launched by HEMATOLOGY ONCOLOGY ASSOCIATES OF CENTRAL NEW YORK · Oct 19, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Able to consent to study
• • Exclusion Criteria from entire study
• • Primary hemostasis diagnosis
• • Von Willebrand Disease
• • Bernard-Soulier syndrome
• • Glanzmann thrombasthenia
• • Idiopathic thrombocytopenic purpura
• • Drug-induced thrombocytopenia
• • Heparin-induced thrombocytopenia
• • Thrombotic thrombocytopenic purpura
• • Hemolytic uremic syndrome
• • Participant is on anticoagulant therapy
• • Specifically thienopyrdines \[Ticlopidine, Clopidogrel\] and GPIIb/IIIa inhibitors \[ReoPro, Aggrastat, Integrilin\]
• • Participant is on medication that contains ASA or aspirin (see list below in Study Procedure)
• • Participant is on nonsteroidal anti-inflammatory agents that are known to induce temporary platelet dysfunction (see list below in Study Procedure)
• • Participant is on non-prescription medications containing aspirin (see list below in Study Procedure)
• • PFA-100 result falls outside of reference interval listed in the package insert (suggested criteria in the PFA-100 Evaluation Protocol as described in the PFA-100 System: Getting Started Guide)
• • If hematocrit is less than 35%
• • If platelets are less than 150 x10\^3/uL
• • Exclusion Criteria from Cohort B but not Cohort A
• • Potential for adverse reactions between current medication and aspirin as dictated by staff pharmacist
• • Allergy to ASA or aspirin
• • Previous allergic reaction to ASA or aspirin
• • Participant is pregnant
• • Asthma, or history of, with nasal polyps and rhinitis
• • Stomach ulcers or bleeding
• • Severe kidney disease
• • Severe liver disease
• • Hemophilia
• • Pregnant or breast feeding